Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

16.75 +0.06 (+0.39%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Summit Therapeutics Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

18 19 Next >

Is Summit Therapeutics Stock a Buy? ↗

September 30, 2024

Its alliance with a successful foreign biotech could be decisive for the stock.

Via The Motley Fool

Regeneron Pharma, Super Micro Computer And Global Payments Are Among Top 10 Large Cap Losers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio? ↗

September 29, 2024

10 worst performing large-cap stocks last week: SMMT, MMYT, MEDP, REGN, GPN, AFRM, SMCI, FTI, FCNCA, NOW. Are they in your portfolio?

Via Benzinga

2 High-Potential Growth Stocks You Shouldn't Overlook ↗

September 29, 2024

These two growth stocks have plenty of room to run.

Via The Motley Fool

Better Rising Biotech: Viking Therapeutics vs. Summit Therapeutics ↗

September 28, 2024

One of them is performing much better than the other this year.

Via The Motley Fool

2 Stocks Up Over 700% in 2024 That Could Soar Even Further ↗

September 25, 2024

These relatively small companies are developing new cancer therapies that could generate billions in annual sales.

Via The Motley Fool

Here's How Much $100 Invested In Summit Therapeutics 5 Years Ago Would Be Worth Today ↗

September 13, 2024

Via Benzinga

Summit Therapeutics Options Trading: A Deep Dive into Market Sentiment ↗

September 11, 2024

Via Benzinga

Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio? ↗

September 22, 2024

10 large-cap stocks worst performers in last week: SMMT -23.61%, KSPI -21.66%, BMRN -16.74%, RIVN -13.26%, FDX -11.08%, BNTX -9.01%, AJG -7.17%, CHWY -6.97%, NVO -6.93%, MUSA -6.90%

Via Benzinga

This Stock Is Crushing Nvidia's Performance This Year: Is It Too Late to Buy? ↗

September 22, 2024

How long will the momentum last?

Via The Motley Fool

Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian

September 19, 2024

Via AB Newswire

Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian

September 19, 2024

Summit Therapeutics' rise could signal emerging opportunities in precision oncology such Nuvectis Pharma (NASDAQ: NVCT), Silexion (NASDAQ:SLXN), and Scorpion leading the charge.

Via News Direct

Is It Too Late to Buy Summit Therapeutics Stock After Its Almost 10X Gain This Year? ↗

September 19, 2024

The sky might be the limit for a biotech company with a pipeline candidate that beat the world's top-selling drug in a late-stage clinical study.

Via The Motley Fool

This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous. ↗

September 18, 2024

There's a lot of hope for ivonescimab, but are investors being a bit too bullish?

Via The Motley Fool

How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery ↗

September 17, 2024

BioNTech is developing a drug similar to Summit's and shares have skyrocketed over the past four trading days.

Via Investor's Business Daily

Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study ↗

September 17, 2024

Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell lung cancer, showing significant improvement in progression-free survival...

Via Benzinga

Here's Why Everyone's Talking About Summit Therapeutics ↗

September 17, 2024

Find out why positive results from a Summit Therapeutics study keep pushing up BioNTech and Instil Bio stock.

Via The Motley Fool

Alphabet To $200? Here Are 10 Top Analyst Forecasts For Monday ↗

September 16, 2024

Via Benzinga

Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024

September 16, 2024

From Summit Therapeutics Inc.

Via Business Wire

Chewy, Broadcom And MicroStrategy Are Among Top 10 Large Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio? ↗

September 15, 2024

These ten stocks saw significant gains last week, with Summit Therapeutics up 98.32% and BioNTech up 31.77%. Analysts also raised price targets for Applovin and Arm Holdings.

Via Benzinga

Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher? ↗

September 14, 2024

A candidate that Instil Bio in-licensed this August is similar to a candidate that recently outperformed the world's top-selling cancer therapy.

Via The Motley Fool

Why Summit Therapeutics Skyrocketed 123% This Week ↗

September 13, 2024

Better-than-expected trial data means Summit's bispecific antibody could replace the blockbuster Keytruda as a standard of care for certain lung cancers.

Via The Motley Fool

Why Summit Therapeutics Stock Is Soaring Again Today ↗

September 12, 2024

This high-flying biotech stock is moving even higher -- and for good reason.

Via The Motley Fool

Signet Jewelers Posts Better-Than-Expected Earnings, Joins NETGEAR, Lovesac And Other Big Stocks Moving Higher On Thursday ↗

September 12, 2024

Via Benzinga

Summit Therapeutics, With 85% Gain This Week, Rockets Again On $235 Million Sale ↗

September 12, 2024

The company is adding onto its success outperforming Merck's top drug in lung cancer patients.

Via Investor's Business Daily

Summit Therapeutics Surges on Trial Results: Time to Buy?

September 12, 2024

Summit Therapeutics has surged almost 100% this week, driven by positive Phase III trial results for its cancer therapy Ivonescimab.

Via MarketBeat

Why Summit Therapeutics (SMMT) Stock Is Rising Today ↗

September 12, 2024

Summit Therapeutics shares are trading higher by 5.1% Thursday morning. The company announced it raised $235 million in net proceeds.

Via Benzinga

Summit Therapeutics Raises $235 Million

September 12, 2024

From Summit Therapeutics Inc.

Via Business Wire

Is Summit Therapeutics a Buy Now? ↗

September 10, 2024

The clinical-stage drugmaker's cancer therapy candidate outperformed Keytruda, the world's top-selling cancer drug.

Via The Motley Fool

Why Summit Therapeutics Rocketed Over 60% Today ↗

September 09, 2024

The company's new lung cancer treatment could unseat Merck's Keytruda in the $50 billion-plus lung cancer treatment market.

Via The Motley Fool

Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday ↗

September 09, 2024

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.